EPIC: At the forefront of biomedical research on eukaryotic pathogens
EPIC: At the forefront of biomedical research on eukaryotic pathogens
Eukaryotic pathogens cause some of the most devastating and intractable diseases in humans, including malaria, amoebic dysentery, sleeping sickness, Chagas disease and fungal meningitis. Globalization has increased such infections in the U.S. Many eukaryotic pathogens are classified as bioterrorism agents and/or neglected tropical diseases.
Clemson University’s Eukaryotic Pathogens Innovation Center — EPIC — is an interdisciplinary research cooperative founded in 2013 that is at the forefront of biomedical research on these devastating pathogens.
EPIC scientists have a lengthy track record of major contributions in this globally important area of research.
RECENT NEWS
EPIC Welcomes Dr. Stephen Dolan
EPIC is excited to announce that Dr. Stephen Dolan will be joining the Center and the Department of Genetics and Biochemistry in Fall 2023 as an Assistant Professor. Dr. Dolan’s research focuses on resolving the molecular mechanisms that dictate interkingdom interaction in polymicrobial infections. Welcome to Clemson, Dr. Dolan!
Congratulations to EPIC students Jillian Milanes, Erin Jones, and Danielle LaVigne on their College of Science awards!
https://news.clemson.edu/top-college-of-science-students-honored/
Congratulations to Dr. Kim Paul on the publishing of her article about Guinea worms in The Conversation!
Read the article here: https://theconversation.com/guinea-worm-a-nasty-parasite-is-nearly-eradicated-but-the-push-for-zero-cases-will-require-patience-199156
Congratulations to Dr. Jim Morris on his recent grant!
Dr. Jim Morris received a two year NIH award of $419k, which will support the development of genetic tools to study the brain-eating amoebae.
Project Name: Approaches for genetic manipulation of Naegleria fowleri
Project Number: NIH R21AI175463
https://reporter.nih.gov/search/6qm8_XjKmUih2d_uQ_qkGw/project-details/10641130
Questions?
For further information about the EPIC please contact us.